In the Media

Viewing stories tagged media

31 January 2018

Starpharma announces DEP cabazitaxel Phase 1/2 Trial

Morningstar reported on Starpharma's announcement regarding the commencement of its phase 1/2 clinical trial for DEP cabazitaxel having received regulatory and ethics approvals. 

Go to article (external link)

23 January 2018

AstraZeneca plans to make better use of Australia’s innovation

The Australian highlighted Starpharma’s partnership with global pharmaceutical company AstraZeneca, noting the application of Starpharma’s DEP® technology platform helps make cancer drugs more effective, more patient-friendly and less toxic.
Go to the article (external link)

21 November 2017

NDA submission for Starpharma’s VivaGel® BV

BioSpectrum Asia reported on Starpharma’s NDA submission for VivaGel® BV, noting that Starpharma is one of the few Australian companies to take a locally developed product to this stage.

Go to article

25 October 2017

Starpharma receives TGA marketing approval for VivaGel® BV

Online financial news portal Finance News Network reported Starpharma received TGA marketing approval for VivaGel® BV, which is expected to be available in pharmacies in the new year under the Fleurstat™ brand.

Go to article

23 October 2017

Morgans Under the Microscope Interview featuring Dr Jackie Fairley

Morgans Under the Microscope series featured Starpharma's CEO, Dr Jackie Fairley, discussing a number of key milestones that are approaching and the licensing arrangements entered into with AstraZeneca. 

Listen to the podcast (external link). 

23 September 2017

Starpharma rockets on cancer drug hope

The Herald Sun noted strong investor interest and support for Starpharma regarding its positive phase 1 DEP® docetaxel trial and that no neutropenia was reported in any patients.

Go to article

28 August 2017

Starpharma featured on Sky Business News

Starpharma CEO Dr Jackie Fairly was interviewed on Sky Business News’ Ticky following the company’s successful Phase 3 trial results for VivaGel® BV for the treatment of recurrent bacterial vaginosis. Dr Fairley discussed the commercial significance of the announcement and liaising with the US FDA to bring the product to market.

To watch the interview, click here

24 August 2017

Starpharma CEO on Finance News Network

Finance News Network featured Dr Jackie Fairley as she discussed the company’s VivaGel® BV Phase 3 results for recurrent bacterial vaginosis, the company's sale of its agrochemical business for $35M, and progress with its DEP® drug delivery programs (both internal and external).

To watch the interview, click here

11 August 2017

Seeking Alpha covers Starpharma

Online stock market insights and research publication Seeking Alpha covered Starpharma’s Phase 3 results for VivaGel® BV for the treatment of recurrent bacterial vaginosis and noted the “substantial upside” of the announcement.

To view the article, click here.

10 August 2017

Starpharma and Monash awarded STEM+ Business fellowships

Biotech news and industry publication Biotech Dispatch covered the news that Starpharma and the Monash Institute of Pharmaceutical Sciences (MIPS) were awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows. The funding allows both Starpharma and Monash to further advance collaborative programs utilising Starpharma’s DEP platform.

To view the article, click here.

9 August 2017

Hope is on the way for one of the world’s most common sexual problems

Investor publication Stockhead recently covered Starpharma’s VivaGel® BV Phase 3 announcement for prevention of recurrent bacterial vaginosis (rBV). The publication noted the significant unmet patient need for BV treatments and how VivaGel® BV targets one of the most common vaginal conditions affecting women of childbearing age. 

Go to article (external link)

9 August 2017

Starpharma readies US NDA for VivaGel® on positive results in Phase 3 Bacterial vaginosis

Biotech trade publication noted Starpharma expects to file an NDA for VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) with the US FDA following the positive results of the Phase 3 trials.

Go to article

6 August 2017

Biotech clinical trials a star performer

Herald Sun covered the investor interest in Starpharma following the positive results of the company’s VivaGel® BV Phase 3 clinical trials for the prevention of recurrent bacterial vaginosis (rBV). Starpharma CEO Dr Jackie Fairley noted VivaGel® BV demonstrated sustained benefits for patients three months after their initial treatment, positioning the company to unlock a multi-million dollar global market.

Go to article (external link)

23 June 2017

Starpharma’s sale of its agrochemical business and technology, expands Agrium’s tech base

The sale of Starpharma’s agrochemical business was recently covered in Farm Weekly, highlighting the unique opportunity that Starpharma’s Priostar® dendrimer technology brings to the agrochemical market and the commercial value Agrium saw in the technology. In the article, Starpharma CEO Dr Jackie Fairley details the sale, including the patent transfer, total sale proceeds and the implications for the Company.

Go to article (external link)

20 June 2017

Starpharma featured on Business IQ, Sky Business News

Starpharma CEO Dr Jackie Fairley was interviewed on Sky Business News where she spoke to Business IQ host James Daggar-Nickson about dendrimer technologies and how the company develops products for a wide range of applications using the platform technology. Dr Fairley also discussed Australian innovation and the company's recent sale of its agrochemical business to global agricultural product giant Agrium.

Go to clip (external link)

14 June 2017

Finance News Network: Starpharma sells Agrochemicals business for $35M

Finance News Network noted Starpharma’s transaction to sell Starpharma Agrochemicals to Agrium Inc. for A$35M in cash consideration. The piece added that cash proceeds from the sale will allow Starpharma to focus on its core pharmaceutical development portfolio.

Go to the article (external link) 

14 June 2017

Starpharma’s sale of its agrochemical business to Agrium for A$35M noted in The Land

The sale of Starpharma’s agrochemical business was covered in The Land, with the article highlighting the innovation behind the Priostar® technology and how Agrium saw the acquisition as a strategic fit for their product portfolio. 

Go to article (external link)

20 April 2017

Starpharma featured on Ticky on Sky Business News

Starpharma CEO Dr Jackie Fairley was interviewed on Ticky on Sky Business News where she discussed the company's VivaGel® portfolio, its DEP® drug delivery technology and its relationship with global pharmaceutical giant AstraZeneca.

 Go to the article (external link)

12 April 2017

Melbourne-based company develops world's first anti-viral condom

 

The ABC notes Starpharma as the Melbourne company developed the world’s first anti-viral condom using its VivaGel® active in the condom lubricant. VivaGel® has been shown to inactivate HIV, herpes, human papillomavirus and the Zika virus in laboratory studies.

 Go to the article (external link)

30 March 2017

VivaGel BV phase 3 trials for prevention of BV completed

Biotech Dispatch reports Starpharma’s recently completed its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis, noting that top-line results are expected in 2Q 2017.

 Go to the article (external link)

12 ... Next

© Starpharma Holdings Limited 2017